Drug Pricing Based on Patient Outcomes

According to this post in FierceHealthcare pharma companies have started adjusting pricing on their drugs to reflect its performance on improving patient outcomes. Merck has agreed to adjust pricing on Januvia and Janumet, which are diabetes drugs, based on how well they treat type 2 diabetes.

Performance-based pricing for meds is extremely rare, but with increased pressure coming from insurance companies it is only a matter of time before we will see more and more pharma companies following this pattern.

Read more about this piece on the NY Times

Related Conference:
Value Driven Pharma Conference

With healthcare costs soaring in the US, payers are tightening their belts and increasingly making coverage decisions based on value. The risk-benefit ratio for all new drugs is under scrutiny as never before and the high cost of healthcare has placed a tremendous amount of pressure on manufacturers to demonstrate the value of products. IIR’s Value-Driven Pharma event brings together stakeholders across the healthcare value chain to exchange best practices

Share this article with your social network, just click below to share now!

Share |